Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 5/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6308451 | 0.84 | MMP1 (0.42) | PSMB5PSMB8CTSBNR1H4LMNA | |
| SCHEMBL18920544 | 0.83 | CYP3A4 (0.42) | PSMB5PSMB8CYP3A4MAPK1CTSB | |
| SCHEMBL21144944 | 0.83 | CYP3A4 (0.42) | PSMB5PSMB8CYP3A4MAPK1CTSB | |
| SCHEMBL21144797 | 0.80 | MAPK1 (0.50) | CYP3A4MAPK1LMNAKMT2AROCK2 | |
| SCHEMBL21144798 | 0.80 | MAPK1 (0.50) | CYP3A4MAPK1LMNAKMT2AROCK2 | |
| SCHEMBL3901670 | 0.80 | MAPK1 (0.50) | CYP3A4MAPK1LMNAKMT2AROCK2 | |
| SCHEMBL2549561 | 0.79 | TACR1 (0.45) | CYP3A4MAPK1LMNAPTGS2EGFR | |
| SCHEMBL6539275 | 0.78 | CNR1 (0.51) | CYP3A4MAPK1LMNAROCK2ROCK1 | |
| SCHEMBL6190633 | 0.78 | CNR1 (0.51) | CYP3A4MAPK1LMNAROCK2ROCK1 | |
| SCHEMBL3897966 | 0.78 | MAPK1 (0.68) | CYP3A4MAPK1MEN1KMT2APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007047575-A2 | PHARMACOLOGICAL TREATMENTS FOR SLEEP-RELATED BREATHING DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-04-26 | — | — | WO | disclosed |
| US-6872748-B2 | Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same | DIGITAL BIOTECH CO., LTD. (KR) | 2005-03-29 | — | — | US | disclosed |
| US-20040063786-A1 | Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same | MEDIFRON DBT CO., LTD. (KR) | 2004-04-01 | — | — | US | disclosed |
| WO-2003027064-A1 | SIMPLIFIED RESINIFERATOXIN ANALOGUES AS VANILLOID RECEPTOR AGONIST SHOWING EXCELLENT ANALGESIC ACTIVITY AND THE PHARMACEUTICAL CO MPOSITIONS CONTAINING THE SAME | DIGITAL BIOTECH CO. LTD,. (KR) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063786-A1 | Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same | TRPV1, OPRL1, GPR180 | PSMB5 1000/4885PSMB8 1451/4885CYP3A4 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.